Alonso Ricardo

Bestine Cong

Camil Sayegh

Charlie Bu

Douangsone D. Vadysirisack

Elizabeth Palmer

Guo-Qing Tang

Jian-Guo Wang

Ketki Dhamnaskar

Michelle D. Hoarty

Nanqun Zhu

Petra W. Duda

Rohit Vyasamneni

Yalan Tang

Zhong Ma

Frontiers in Immunology

Directory of Open Access Journals

Frontiers in ImmunologyOPEN ACCESSEDITED AND REVIEWED BYMarie-Agnes Dragon-Durey,Université Paris Cité, France*CORRESPONDENCEGuo-Qing TangGuoQing.Tang@ucb.com†PRESENT ADDRESSESKetki Dhamnaskar,Nurix Therapeutics, San Francisco,CA, United StatesMichelle D. Hoarty,Dyne Therapeutics, Waltham,MA, United StatesDouangsone D. Vadysirisack,Dianthus Therapeutics, Waltham,MA, United StatesZhong Ma,Mariana Oncology, Watertown,MA, United StatesRohit Vyasamneni,BioNTech SE, Cambridge,MA, United StatesNanqun Zhu,Avilar Therapeutics, Waltham,MA, United StatesCamil Sayegh,Mitochondria Emotion Inc., Cambridge,MA, United StatesAlonso Ricardo,Mariana Oncology, Watertown,MA, United StatesRECEIVED 23 August 2023ACCEPTED 08 September 2023PUBLISHED 25 September 2023CITATIONTang G-Q, Tang Y, Dhamnaskar K,Hoarty MD, Vyasamneni R,Vadysirisack DD, Ma Z, Zhu N, Wang J-G,Bu C, Cong B, Palmer E, Duda PW,Sayegh C and Ricardo A (2023)Corrigendum: Zilucoplan, a macrocyclicpeptide inhibitor of human complementcomponent 5, uses a dual mode of actionto prevent terminal complement pathwayactivation.Front. Immunol. 14:1282155.doi: 10.3389/fimmu.2023.1282155COPYRIGHT© 2023 Tang, Tang, Dhamnaskar, Hoarty,Vyasamneni, Vadysirisack, Ma, Zhu, Wang,Bu, Cong, Palmer, Duda, Sayegh andRicardo. This is an open-access articledistributed under the terms of the CreativeCommons Attribution License (CC BY). Theuse, distribution or reproduction in otherforums is permitted, provided the originalauthor(s) and the copyright owner(s) arecredited and that the original publication inthis journal is cited, in accordance withaccepted academic practice. No use,distribution or reproduction is permittedwhich does not comply with these terms.TYPE CorrectionPUBLISHED 25 September 2023DOI 10.3389/fimmu.2023.1282155Corrigendum: Zilucoplan, amacrocyclic peptide inhibitor ofhuman complement component5, uses a dual mode of action toprevent terminal complementpathway activationGuo-Qing Tang1*, Yalan Tang1, Ketki Dhamnaskar2†,Michelle D. Hoarty3†, Rohit Vyasamneni2†,Douangsone D. Vadysirisack3†, Zhong Ma3†, Nanqun Zhu3†,Jian-Guo Wang1, Charlie Bu1, Bestine Cong1, Elizabeth Palmer1,Petra W. Duda1, Camil Sayegh3† and Alonso Ricardo2†1UCB Pharma, Cambridge, MA, United States, 2Ra Pharmaceuticals, Cambridge, MA, United States,3UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United StatesKEYWORDScomplement activation, C5 cleavage, C5 R885 variants, C5b6, MAC formation,macrocyclic peptide inhibitor, RBC hemolysis, permeabilityA corrigendum onZilucoplan, a macrocyclic peptide inhibitor of humancomplement component 5, uses a dual mode of action to preventterminal complement pathway activationby Tang G-Q, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N,Wang J-G, Bu C, Cong B, Palmer E, Duda PW, Sayegh C and Ricardo A (2023) Front. Immunol.14:1213920. doi: 10.3389/fimmu.2023.1213920In the published article, there were errors in Figure 3 as published. In part A, the binding site isthe “zilucoplan binding site”, rather than the “eculizumab binding site”. In part D, “nonspecificproteinases” should be “nonspecific proteases”. The corrected Figure 3 and its captionappear below.In the published article, there was an error. The Introduction incorrectly states thatzilucoplan is composed of a 15-amino acid macrocyclic peptide including three unnaturalamino acids. Zilucoplan is composed of a 15-amino acid macrocyclic peptide includingfour unnatural amino acids.A correction has been made to Introduction, paragraph 4. This sentence previously stated:frontiersin.org01Tang et al. 10.3389/fimmu.2023.1282155“It is composed of a 15-amino acid macrocyclic peptide, includingthree unnatural amino acids, designed to inhibit TCC activation”The corrected sentence appears below:“It is composed of a 15-amino acid macrocyclic peptide, includingfour unnatural amino acids, designed to inhibit TCC activation”The authors apologize for these errors and state that these donot change the scientific conclusions of the article in any way. Theoriginal article has been updated.Frontiers in Immunology 02Publisher’s noteAll claims expressed in this article are solely those of the authorsand do not necessarily represent those of their affiliatedorganizations, or those of the publisher, the editors and thereviewers. Any product that may be evaluated in this article, orclaim that may be made by its manufacturer, is not guaranteed orendorsed by the publisher.BC DAFIGURE 3Zilucoplan destabilizes C5b6 and inhibits C5b6-mediated hemolysis lysis. (A) Schematic depiction (using PyMOL 2.4.0 based on PDB 4a5w) of theC5b6 complex. C5b is in gray except for the C5 TED in yellow, proposed binding sites for zilucoplan peptidyl portion based on a peptide analog(unpublished data) in pink, and C6 in lime. (B) Native gel analysis of the C5b6 complex in the presence and/or absence of zilucoplan. Lanes 1 and 6:C5b6 incubated at 37°C/h with (Lane 1) or without (Lane 6) 1% DMSO. Lanes 2–6: C5b6 after incubation with various concentrations of zilucoplan (in1% DMSO) at 37°C for 1 h prior to gel loading. Lanes 7 and 8: C5 and C6 alone. (C) Zilucoplan inhibited the plasmin-mediated lysis of EA. Plasminwithout or with increasing concentrations of zilucoplan was added to a mixture of C5 and C6 and incubated for 1 h. The plasmin reaction solutionwas then added to EA before mixing with purified C7, C8, and C9 to proceed with the lysis. More details are described in the Materials and Methods.Note that no sera were used to exclude any contribution by C3/C5 convertases. (D) A schematic diagram of the dual mechanism of action forzilucoplan: zilucoplan binds C5 (gray/dark blue) to prevent C5 cleavage into C5a (dark blue) and C5b (gray) by C5 convertases (light blue) andremains on C5b to prevent the formation of C5b6 (C6 in green) mediated by nonspecific proteases, both contributing to the blockade of MACformation (red). TED, thioester-like domain; DMSO, dimethyl sulfoxide.frontiersin.org

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1282155/pdf?isPublishedV2=False

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals